AUS
NZ
UK
CA
USA
IND
Highlight
- Principal Financial Group Inc. slightly reduced its stake in Bio-Rad Laboratories, now holding 44,107 shares worth $14,490,000.
- A range of institutional investors have adjusted their holdings in Bio-Rad, showcasing diverse investment strategies.
- Market analysts have mixed opinions with a moderate buy rating and price target averaging $395.20.
The financial landscape for Bio-Rad Laboratories reflects dynamic investment activities in recent months. Principal Financial Group Inc. registered a nominal decrease in its holdings, revealing a 0.5% reduction as evidenced in its latest SEC Form 13F filing. This anticipates ownership of 44,107 shares in Bio-Rad, corresponding to approximately 0.16% of the company's collection, valued at $14,490,000 by the period's conclusion.
Similarly, other significant financial entities have revised their positions within Bio-Rad. Strategic Financial Concepts LLC and Lecap Asset Management Ltd. made new investments during the fourth quarter, valuing $3,561,000 and $510,000, respectively. Meanwhile, Mawer Investment Management Ltd. amplified its stake by 63.0% in the third quarter, acquiring 217,885 shares, which were valued at $72,900,000 post increase. Verition Fund Management LLC also expanded its holdings remarkably by 193.3%, capturing 3,470 shares worth $1,161,000. New positions, like those from Diversified Trust Co at $958,000, further highlight the shifting investment landscape among institutional players.
Performance and Analyst Ratings
Bio-Rad Laboratories has elicited varied reactions from financial analysts. It encountered a moderate downgrade, as seen with StockNews.com reassessing their previous buy recommendation to a hold rating. Conversely, the Royal Bank of Canada maintains an outperform rating with a price expectancy of $481.00. Citigroup conveys confidence with an increased price target from $400.00 to $450.00, whereas Wells Fargo & Company adjusted their projection from $360.00 to $345.00, categorizing the company as having equal weight.
Despite the diverging analyst outlooks, the company's stock commenced at $276.85 on the start of the reported day. This is below its moving average prices of $329.49 for 50 days and $333.37 for 200 days respectively. Bio-Rad Laboratories maintains a market cap of $7.75 billion, characterized by a P/E ratio of -4.26, and houses a beta figure of 0.90, underlining the company's market sensitivity. Notably, Bio-Rad’s financials reflect resilient liquidity, with a quick ratio of 4.85, a current ratio of 6.48, and modest debt exposure with a debt-to-equity ratio of 0.18.
Company Overview
Bio-Rad Laboratories excels as a prominent entity in the medical research field, focusing on the production and distribution of life science research and clinical diagnostic products. The company's operational reach extends across the United States, Europe, Asia, Canada, and Latin America. It is bifurcated into two primary segments: Life Science and Clinical Diagnostics. Its product range encompasses instruments, systems, reagents, and consumables pivotal in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety sectors.
Market Outlook
In the current financial year, Bio-Rad Laboratories anticipates achieving an EPS of 10.81, following its recent report of $2.90 EPS for the quarter, which slightly eclipsed analysts' projections at $2.86. This performance points to the company’s capacity to maintain a positive trajectory in return on equity, despite a negative net margin reported at 71.86%.
